Shanghai, China - MicroPort® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort® CardioFlow, stock code: 02160.HK) recently announced that following Alwide® Plus Balloon Catheter, the second generation of balloon catheter, Its self-developed new generation Transcatheter Aortic Valve Implantation (" TAVI ") product VitaFlow Liberty® Transcatheter Aortic Valve and Retrivable Delivery System (" VitaFlow Liberty® ") has received marketing approval from the Saudi Food and Drug Administration (SFDA).
As China's first and the world's only electric retrievable transcatheter aortic valve system, VitaFlow Liberty® was approved for marketing by the NMPA in 2021. Since then, it has been successively launched in multiple overseas countries and obtained the EU CE-MDR certification in 2024, becoming the first domestically developed TAVI system approved by EU. To date, the VitaFlow® series TAVI solution along with its accessory - the Alwide® series Balloon Catheter, has successfully covered nearly 700 core hospitals in 10 countries and regions, treating over 10,000 patients with aortic valve diseases worldwide.
Saudi Arabia, one of the fastest-growing major economies globally and the largest economy in the Middle East, possesses tremendous potential in the high-end medical device market. The approval of VitaFlow Liberty® in Saudi Arabia will accelerate its internationalization process and benefit more patients with structural heart diseases worldwide.
©Copyright 1998-2023, MicroPort CardioFlow Medtech Corporation. All rights reserved. | 网站备案/许可证号:沪ICP备2023023560号 沪公网安备 31011502014876号
互联网药品信息服务资格证书编号:(沪)-非经营性 - 2024 - 0135
“MicroPort CardioFlow”及“ are registered trademarks of MicroPort CardioFlow Medtech Corporation.